This is the authors' abstract. We don't add key points for this paper.
To study safety, efficacy and weight loss with ADO09, a co-formulation of insulin A21G and pramlintide, in type 1 diabetes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: